Athenex, Inc. (ATNX)

NASDAQ: ATNX · IEX Real-Time Price · USD
0.194
-0.005 (-2.51%)
Dec 5, 2022 3:48 PM EST - Market open
-2.51%
Market Cap 31.32M
Revenue (ttm) 119.71M
Net Income (ttm) -173.63M
Shares Out 139.47M
EPS (ttm) -1.78
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 598,230
Open 0.205
Previous Close 0.199
Day's Range 0.19 - 0.205
52-Week Range 0.162 - 1.74
Beta 1.10
Analysts Buy
Price Target 2.21 (+1,039.2%)
Earnings Date Nov 3, 2022

About ATNX

Athenex, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of cancer. It operates through three segments: Oncology Innovation Platform, Global Supply Chain Platform, and Commercial Platform. The company's Orascovery product candidates include Oral paclitaxel and encequidar, an oral dosage form, which is in Phase III trial for metastatic breast cancer, as well as various clinical studies in cutaneous angiosarcoma, advanced gastric cancer, and advanced solid malignancies. It... [Read more]

Industry Biotechnology
IPO Date Jun 14, 2017
CEO Johnson Lau
Employees 652
Stock Exchange NASDAQ
Ticker Symbol ATNX
Full Company Profile

Financial Performance

In 2021, Athenex's revenue was $120.18 million, a decrease of -16.77% compared to the previous year's $144.39 million. Losses were -$199.77 million, 36.7% more than in 2020.

Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for ATNX stock is "Buy." The 12-month stock price forecast is 2.21, which is an increase of 1,039.18% from the latest price.

Price Target
$2.21
(1,039.18% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Athenex Announces Positive Results of Special Stockholder Meeting

BUFFALO, N.Y., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 week ago - GlobeNewsWire

Athenex Announces Closing of the Sale of its China API Business

BUFFALO, N.Y., Nov. 21, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

2 weeks ago - GlobeNewsWire

Athenex (ATNX) Reports Q3 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of 12.50% and 16.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

Athenex Announces Receipt of Positive Nasdaq Listing Determination

Nasdaq Hearing Panel grants continued listing of Athenex and extension to regain compliance with the minimum bid price requirement Nasdaq Hearing Panel grants continued listing of Athenex and extension ...

1 month ago - GlobeNewsWire

Athenex Provides Third Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., Nov. 03, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

1 month ago - GlobeNewsWire

Athenex to Provide Corporate and Financial Update for the Third Quarter 2022 on November 3, 2022

BUFFALO, N.Y., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

1 month ago - GlobeNewsWire

Athenex Files Definitive Proxy Statement for Special Stockholder Meeting

BUFFALO, N.Y., Oct. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

1 month ago - GlobeNewsWire

Athenex to Participate in the H.C. Wainwright 24th Annual Global Investment Conference

BUFFALO, N.Y., Sept. 06, 2022 (GLOBE NEWSWIRE) --  Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the tr...

2 months ago - GlobeNewsWire

Athenex, Inc. Announces Pricing of $30 Million Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel ther...

3 months ago - GlobeNewsWire

Athenex, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Warrants

BUFFALO, N.Y., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (“Athenex”) (Nasdaq: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel ther...

3 months ago - GlobeNewsWire

Athenex (ATNX) Reports Q2 Loss, Lags Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of -76.92% and 6.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

Athenex Provides Second Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., July 28, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

4 months ago - GlobeNewsWire

Athenex Announces Publication of Data from Phase 3 Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous...

BUFFALO, N.Y., July 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

4 months ago - GlobeNewsWire

Athenex to Provide Corporate and Financial Update for the Second Quarter 2022 on July 28, 2022

BUFFALO, N.Y., July 21, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

4 months ago - GlobeNewsWire

Athenex Announces Entry into Agreement to Sell its China API Business to TiHe Capital (Bejing) Co., Ltd.

BUFFALO, N.Y., July 11, 2022 (GLOBE NEWSWIRE) --  Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

4 months ago - GlobeNewsWire

Athenex to Participate in Truist Securities Cell Therapy Symposium

BUFFALO, N.Y., June 23, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the trea...

5 months ago - GlobeNewsWire

Athenex Announces Sale of Revenues from U.S. and European Royalty and Milestone Interests in Klisyri® (tirbanibulin) ...

BUFFALO, N.Y., June 22, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

5 months ago - GlobeNewsWire

Athenex Appoints Darrel P. Cohen, MD, PhD as Chief Medical Officer of Cell Therapy

BUFFALO, N.Y., June 08, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for t...

5 months ago - GlobeNewsWire

Athenex (ATNX) Reports Q1 Loss, Tops Revenue Estimates

Athenex (ATNX) delivered earnings and revenue surprises of -50% and 16.41%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

6 months ago - Zacks Investment Research

Athenex Provides First Quarter 2022 Financial Results and Business Update

BUFFALO, N.Y., May 10, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for th...

6 months ago - GlobeNewsWire

Athenex, Texas Children's Cancer Center, and the Center for Cell and Gene Therapy at Baylor College of Medicine to Pr...

BUFFALO, N.Y., May 02, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treat...

7 months ago - GlobeNewsWire

Athenex to Provide Corporate and Financial Update for the First Quarter 2022 on May 10, 2022

BUFFALO, N.Y., April 29, 2022 (GLOBE NEWSWIRE) -- Athenex (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the tre...

7 months ago - GlobeNewsWire

Athenex (ATNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

Athenex (ATNX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

Athenex Presents Interim Data from Phase 1 ANCHOR Study of KUR-502 (Allogeneic CD19 CAR-NKT Cells) in Relapsed or Ref...

BUFFALO, N.Y., April 25, 2022 (GLOBE NEWSWIRE) -- Athenex, Inc., (NASDAQ: ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for ...

7 months ago - GlobeNewsWire

Athenex Provides Fourth Quarter and Full Year 2021 Financial Results and Provides Business Update

Announces Strategic Pivot to Focus on Cell Therapy Programs

8 months ago - GlobeNewsWire